New research reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional lifestyle programs.
Published data in a prominent medical journal shows that while obese people often shed substantial amounts of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Users using these treatments must be informed of the danger of quick rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight within about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
The team point out that individuals who lose weight through diet and exercise generally experience a slower creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Nutrition scientists suggest the way of the drugs is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to appetite is unsuppressed, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts contend that, given the likelihood of weight regain, the treatment is often ongoing.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," similar to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the medication explain a powerful resurgence of hunger.
"I experienced a trigger activating and I was suddenly extremely hungry," said a patient.
The struggle is compounded if patients have not developed sustainable dietary or behavioural changes during treatment.
Growing Use
Figures indicate that millions of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while the jabs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on combined behavioural support.
